Brian McKelligon - 13 Mar 2024 Form 4/A Insider Report for Akoya Biosciences, Inc. (AKYA)

Role
President and CEO, Director
Signature
/s/ Brian McKelligon
Issuer symbol
AKYA
Transactions as of
13 Mar 2024
Net transactions value
-$34,770
Form type
4/A
Filing time
22 Mar 2024, 17:51:44 UTC
Date Of Original Report
14 Mar 2024
Previous filing
04 Mar 2024
Next filing
22 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKYA Common Stock Options Exercise $2,272 +7,500 +3.2% $0.3030* 239,368 13 Mar 2024 Direct
transaction AKYA Common Stock Sale $37,042 -7,500 -3.1% $4.94 231,868 13 Mar 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKYA Employee Stock Option (Right to Buy) Options Exercise $0 -7,500 -2.5% $0.000000 298,129 13 Mar 2024 Common Stock 7,500 $0.3030 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Brian M. McKelligon dated August 16, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.81 to $5.08, inclusive. The reporting person undertakes to provide to Akoya Biosciences, Inc., any security holder of Akoya Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
F3 The option, representing a right to purchase a total of 353,129 shares, became exercisable as follows: one-fourth of the shares vested on July 14, 2018 with the remaining shares vesting in 36 equal monthly installments beginning on August 14, 2018, subject to reporting person's continuous employment.